The short answer: ChondroFiller is self-funded private treatment

ChondroFiller® is not available on the NHS. In the UK, it is designated as self-funded private treatment — neither commissioned by NHS England nor routinely covered by private medical insurance (PMI).

London Cartilage Clinic at 66 Harley Street is the first and currently the only UK clinic to offer ChondroFiller® as an injectable treatment. Access requires no GP referral, no insurance pre-approval, and no NHS pathway: patients can self-refer directly and book a consultation at their own pace.

The sections below cover what the private pathway involves — how the injection works, what the pricing structure includes, and whether there is any realistic route to insurer reimbursement — so that anyone weighing up whether to proceed has a clear picture of the practical commitment involved.

Why ChondroFiller isn't commissioned by the NHS

The absence from NHS provision reflects how the health service commissions treatments rather than any gap in ChondroFiller®'s clinical standing. NHS England funds interventions that have passed through national appraisal frameworks — typically NICE technology appraisals or commissioned service specifications — a process that prioritises treatments across the full disease spectrum and balances population-level resource allocation. CE-marked specialist devices operating in a narrow cartilage-preservation niche, such as ChondroFiller®, are not routinely entered into those pathways at this stage of their adoption.

The NHS does fund cartilage interventions: microfracture and autologous chondrocyte implantation (ACI) are available via the NHS Bluebook for eligible patients, but these are surgical, theatre-based procedures on a separate and longer-established commissioning pathway. ChondroFiller® represents a more recent approach — an injectable, outpatient scaffold — that has not yet been assessed within the same national framework.

London Cartilage Clinic's own FAQ makes the distinction clearly: the NHS serves all disease spectrums with different resource priorities, whilst a dedicated private cartilage clinic operates with a narrower focus and access to techniques not yet in routine commissioning. Neither model is a criticism of the other.

How to access ChondroFiller privately in the UK

Suitability is established at an initial consultation led by Professor Paul Y.F. Lee, Consultant Orthopaedic Surgeon, who reviews defect characteristics, available imaging, and clinical presentation to determine whether ChondroFiller® is appropriate for that patient. The clinic holds ICRS Teaching Centre of Excellence status, reflecting the cartilage specialism that underpins that assessment process.

There is no published upper age limit and no strict defect-size ceiling for candidacy — a meaningful distinction from some surgical cartilage procedures, which specify minimum or maximum defect dimensions or exclude older patients on physiological grounds. Most patients are treated with a single box; larger or multi-compartmental defects may require two or three boxes, determined at the assessment stage.

Once candidacy is confirmed, the injection is delivered as a standard outpatient appointment under real-time ultrasound guidance. There is no general anaesthetic, no surgical incision, and no overnight stay; the procedure typically takes 30 to 45 minutes from start to finish. A six-week follow-up is included in the package price. Patients can contact the clinic directly at londoncartilage.com to arrange an initial consultation.

What ChondroFiller costs as a private treatment

Guide costs at London Cartilage Clinic follow a straightforward volume-based structure. A single box — sufficient for most focal defects — is priced at £3,000. Two boxes cost £5,500, and three boxes £8,000. Each figure is all-inclusive: nothing is billed separately on top of the quoted price. Exact costs are confirmed at consultation once the treating clinician has reviewed defect characteristics and determined how many boxes the case requires.

For patients with more advanced osteoarthritis — Kellgren-Lawrence Grade III or IV — combination packages are available. The dual-injection plan pairing ChondroFiller® with Arthrosamid® is priced from £6,000. It is worth understanding that these two products work through distinct mechanisms: ChondroFiller® is a regenerative collagen scaffold designed to support the body's own repair processes at the cartilage surface, whereas Arthrosamid® is a polyacrylamide hydrogel that integrates into the synovial lining to cushion the joint. They address different aspects of the same joint problem and should not be thought of as interchangeable. A tri-active programme adding mesenchymal stem cell therapy to the combination reaches £11,000.

Beyond single-episode treatment, a longitudinal lifetime programme — incorporating biennial ChondroFiller® top-ups and annual MRI imaging — is offered for patients seeking sustained joint preservation over the longer term.

All figures above are guide costs confirmed by the treating clinic; final pricing is established at the point of clinical assessment.

Private medical insurance and ChondroFiller

Standard UK private medical insurance policies do not routinely cover ChondroFiller®, and patients should plan on the basis of self-funding rather than assumed reimbursement. That said, coverage is not categorically impossible. Internal clinic documentation from October 2025 records that billing under CCSD codes W3111 (cartilage regeneration with collagen scaffold) and W8500 has produced case-by-case approvals from Bupa, Aviva, and WPA — though outcomes vary and no insurer has committed to routine cover.

The practical step for any patient with an active PMI policy is to contact their insurer before booking and obtain written pre-authorisation, specifying the treatment and the relevant billing codes. Verbal assurances alone are not a reliable basis for assuming reimbursement. For patients who proceed without pre-authorisation, the clinic can supply an itemised invoice to support an independent claim submission after the fact — though approval at that stage is less certain still.

The honest framing is this: PMI cover is a possibility worth exploring, not a reasonable expectation. Patients who secure written pre-authorisation in advance are in the strongest position; those who cannot should proceed with a clear understanding that full self-funding is the most likely outcome.

What the treatment involves and whatoutcomes to expect

The mechanism behind ChondroFiller® is central to understanding what improvement is realistic and over what timeframe. Rather than delivering live cells, the product acts as an acellular collagen scaffold — a structure that gels in situ at the defect site and recruits the patient's own progenitor cells from surrounding synovium and subchondral bone. Those recruited cells differentiate into chondrocytes and begin building new tissue through a process known as acellular matrix-induced chondrogenesis. The repair unfolds gradually over approximately six to twelve months; the injection supports the body's own processes rather than delivering an immediate structural fix.

On published outcomes, IKDC patient-reported scores improve by approximately 30 points at one year — a shift considered clinically meaningful. The important caveat is that the evidence base currently consists largely of observational studies and manufacturer-sponsored research; large independent randomised controlled trials remain limited. Those figures are a useful benchmark, not a guarantee, and individual results depend on defect characteristics, joint loading, and patient biology.

Recovery centres on activity modification and a graduated return to normal loading rather than a surgical rehabilitation programme. There is no ward admission, no wound care, and no post-operative physiotherapy regime of the kind that follows cartilage surgery. A clinical review at six weeks is included in the treatment package.

For a patient at the decision stage, the key question is whether their specific defect and symptom picture makes them a suitable candidate for this pathway — which is what a structured clinical assessment is designed to determine.